Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.

American heart journal

Volumn 143, Issue 2, 2002, Pages 242-248

  Mahaffey, Kenneth W ^a   Roe, Matthew T ^a   Dyke, Christopher K ^a   Newby, L Kristin ^a   Kleiman, Neal S ^a   Connolly, Patty ^a   Berdan, Lisa G ^a   Sparapani, Rodney ^a   Lee, Kerry L ^a   Armstrong, Paul W ^a   Topol, Eric J ^a   Califf, Robert M ^a   Harrington, Robert A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ELECTROCARDIOGRAPHY; ENZYME ASSAY; HEART INFARCTION; HUMAN; METHODOLOGY; MULTICENTER STUDY; PEER REVIEW; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ELECTROCARDIOGRAPHY; ENZYME TESTS; HUMANS; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PEER REVIEW, RESEARCH; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0036480190     PISSN: None     EISSN: 10976744     Source Type: Journal    
DOI: None     Document Type: Article

References (0)